Cognitive Enhancement Therapy for Early-Stage Schizophrenia

Completed · Phase 3

Conditions studied: Schizophrenia

In brief

This study will determine the effectiveness of cognitive enhancement therapy (CET) in treating cognitive abnormalities in people experiencing the early stages of schizophrenia.

Key facts

Study ID

NCT00167362

Run by

Beth Israel Deaconess Medical Center

People needed

67

Starts

2001-08-01

Expected to finish

2016-12-01

Last updated by the study team

2017-01-10

Who can join

Age: 16 and older, up to 51. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• DSM-IV diagnosis of schizophrenia, schizoaffective or schizophreniform disorder at the time of initial assessment
• Pre-treatment illness duration an average of 5 years, not to exceed 8 years
• Stable positive symptoms (e.g., if present do not grossly interfere with behavior such as command hallucinations or delusions)
• Currently maintained and compliant with prescribed antipsychotic medication
• Socially and cognitively disabled, e.g., meet criteria on a Cognitive Style Scale (score greater than or equal to 7), and Social Cognition Disability Scale (score greater than or equal to 12).

You may not qualify if…

• Alcohol/drug abuse or dependence that has significantly interfered with adjustment in the past two months (e.g., patients currently undergoing D and A treatment must successfully complete their recovery program prior to referral)
• Organic brain syndrome, including HIV illness (due to its effect on CNS function)
• IQ below 80 or language skills below the sixth grade level
• Medical contraindications that preclude an appropriate antipsychotic medication
• Persistent suicidality

Where it is running

• University of Pittsburgh — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.